




## The Open PHACTS Discovery Platform

Semantic Data Integration for Life Sciences









Resulting in a sales revenu

Generic Competition


Value of patent expiries 2001-2015 (constant







#### Figure 1: The decline in R&D productivity



#### NIME:

New chemical or biological prescription therapeutic: excludes vaccines, antigens and combination therapies which do not include at least one new constituents


Source: FDA CDER, PhRMA and PricewaterhouseCoopers analysis
Note: Data on R&D spending for non-PhRMA companies are not included here.





#### Pre-competitive Informatics:

Pharma are all accessing, processing, storing & re-processing external research data



Lowering industry firewalls: pre-competitive informatics in drug discovery Nature Reviews Drug Discovery (2009) 8, 701-708 doi:10.1038/nrd2944





#### Over the last decade

- Data has become more open
- Data has become better represented (Standards)
- Major providers are becoming more organised (NCBI, EBI, FDA)

#### **BUT**

Integration across sources, and across providers is still a gap















#### The Innovative Medicines Initiative

- EC funded publicprivate partnership for pharmaceutical research
- Focus on key problems
  - Efficacy, Safety,
     Education &
     Training,
     Knowledge
     Management



#### The Open PHACTS Project

- Create a semantic integration hub ("Open Pharmacological Space")...
- Runs 2011-2014, ENSO till 2016
- Deliver services to support on-going drug discovery programs in pharma and public domain
- Leading academics in semantics, pharmacology and informatics, driven by solid industry business requirements
- 31 academic partners, 9 pharmaceutical companies, 3 software SMEs
- Work split into clusters:
  - Technical Build
  - Scientific Drive
  - Community & Sustainability





# Open PHACTS Mission: Integrate Multiple Research Biomedical Data Resources Into A Single Open & Free Access Point






"What is the selectivity profile of known p38 inhibitors?"



"Let me compare MW, logP and PSA for known oxidoreductase inhibitors"







**ChEMBL** 

DrugBank

Gene Ontology

Wikipathways

GeneGo

ChEBI

**UniProt** 

**UMLS** 

**GVKBio** 

ConceptWiki

ChemSpider

TrialTrove

TR Integrity





#### **Business Question Driven Approach**

Number	sum	Nr of 1	Question									
15	12	9	All oxidoreductase inhibitors active <100nM in both human and mouse									
18	14	8	Given compound X, what is its predicted secondary pharmacology? What are the on and off,target safety concerns for a compound? What is the evidence and how reliable is that evidence (journal impact factor, KOL) for findings associated with a compound?									
24	13	8		Given a target find me all actives against that target. Find/predict polypharmacology of actives.  Determine ADMET profile of actives.								
32	13	8	For a given	-accesses services								
37	13	8	The curren	006-300/A 2-00/25/30	Volume 18, Issues 17–18, September 2013, Pages 843–852							
38	13	8	Retrieve all structure (v									
41	13	8	A project is compounds the target of level of the	Scientific o	competency questions as the basis for semantically							
44	13	8	Give me al	enriched open pharmacological space development								
46	13	8	Give me th (disease)	Kamal Azzaoui <sup>1</sup> , Edgar Jacoby <sup>14</sup> , Stefan Senger <sup>2</sup> , Emiliano Cuadrado Rodríguez <sup>3</sup> , Mabel Loza <sup>3</sup> , Barba Zdrazil <sup>4</sup> , Marta Pinto <sup>4</sup> , Antony J. Williams <sup>5</sup> , Victor de la Torre <sup>6</sup> , Jordi Mestres <sup>7</sup> , Manuel Pastor <sup>7</sup> , Olivie								
59	14	8	Identify all	Taboureau <sup>8</sup> , Matt	hias Rarey <sup>9</sup> , Christine Chichester <sup>10</sup> , Steve Pettifer <sup>11</sup> , Niklas Blomberg <sup>12, a</sup> , Lee							



#### **Drug Discovery Today**



#### Scientific competency questions as the basis for semantically enriched open pharmacological space development

Kamal Azzaoui<sup>1</sup>, Edgar Jacoby<sup>14</sup>, Stefan Senger<sup>2</sup>, Emiliano Cuadrado Rodríguez<sup>3</sup>, Mabel Loza<sup>3</sup>, Barbara Zdrazil<sup>4</sup>, Marta Pinto<sup>4</sup>, Antony J. Williams<sup>5</sup>, Victor de la Torre<sup>6</sup>, Jordi Mestres<sup>7</sup>, Manuel Pastor<sup>7</sup>, Olivier Taboureau<sup>8</sup>, Matthias Rarey<sup>9</sup>, Christine Chichester<sup>10</sup>, Steve Pettifer<sup>11</sup>, Niklas Blomberg<sup>12, a</sup>, Lee Harland<sup>13</sup>, Bryn Williams-Jones<sup>13</sup>, Gerhard F. Ecker<sup>4</sup>, ≜ . ≅





#### The Open PHACTS Discovery Platform

- Cloud-Based "Production" Level System. Secure & Private
- Guided By Business
   Questions
- Uses Semantic Web
   Technology <u>But</u> provides
   a simple REST-ful API for
   everyone else



#### **Drug Discovery Today**

Volume 18, Issues 17-18, September 2013, Pages 843-852



Review

Scientific competency questions as the basis for semantically enriched open pharmacological space development

Kamal Azzaoui¹, Edgar Jacoby¹⁴, Stefan Senger², Emiliano Cuadrado Rodríguez³, Mabel Loza³, Barbara Zdrazii⁴, Marta Pinto⁴, Antony J. Williams⁵, Victor de la Torre⁶, Jordi Mestres⁻, Manuel Pastor⁻, Olivier Taboureau⁶, Matthias Rarey⁶, Christine Chichester¹⁰, Steve Pettifer¹¹, Niklas Blomberg¹², ĕ, Lee Harland¹³, Bryn Williams-Jones¹³, Gerhard F, Ecker⁴, ♣ . ™

http://dx.doi.org/10.1016/j.drudis.2013.05.008



Web Semantics: Science, Services and Agents on the World Wide Web





In Press, Accepted Manuscript - Note to users

API-centric Linked data integration: The open PHACTS discovery platform case study

Paul Groth<sup>a, ▲ ™, ™, Antonis Loizou<sup>a</sup>, Alasdair J.G. Gray<sup>d</sup>, Carole Goble<sup>b</sup>, Lee Harland<sup>c</sup>, Steve Pettifer<sup>b</sup> http://dx.doi.org/10.1016/j.websem.2014.03.003</sup>






#### HOW STANDARDS PROLIFERATE: (SEE: A/C CHARGERS, CHARACTER ENCODINGS, INSTANT MESSAGING, ETC.)

SITUATION: THERE ARE 14 COMPETING STANDARDS.





500N:

15 COMPETING STANDARDS.

http://imgs.xkcd.com/comics/standards.png

- Basic Semantic web standards
  - SPARQL 1.1, RDF(S), SKOS
- Dataset descriptions
  - Vocabulary of Interlinked Datasets (VoID)
  - VoID linkset descriptions


- QUDT Quantities, Units, Dimensions and Types
- Provenance
  - W3C PROV, PAV, Nanopublications
- BioPortal, ConceptWiki, ChEMBL, identifiers.org, Uniprot, ChemSpider





#### HELLO my name is


P12047
X31045








#### **Are These Two Molecules The Same(\*)**









\*Really: Is it sensible to combine data associated with these two molecules?





#### **Data Licensing Solution**

Chose John Wilbanks as consultant

A framework built around STANDARD well-understood Creative Commons licences – and how they interoperate

#### Deal with the problems by:

- Interoperable licences
- Appropriate terms
- Declare expectations to users and data publishers
- One size won't fit all requirements



Compatibility chart		Terms that may be used for a derivative work or adaptation								
Companionity C	BY	BY-NC	BY-NC-ND	BY-NC-SA	BY-ND	BY-SA	PD			
	PD									
	BY									
	BY-NC									
Status of original work	BY-NC-ND									
	BY-NC-SA									
	BY-ND									
	BY-SA									







Sign in | Sign up

Developer Home

Want help?

Documentation

Get my API keys!

Featured Apps

#### **Create!**

Build with the Open PHACTS Discovery Platform. The platform provides a convenient API to query across multiple pharmacology datasets.

You'll find complete documentation for the API in our <u>documentation</u> section. You'll need an API key to use the platform. <u>Sign-up</u> is free. For more information on the project, check out <u>www.openphacts.org</u>.

#### News:

- We are currently in beta. <u>Let us know</u> if you have a feature request or bug report.
- April 22, 2013 launch of public beta at the <u>4th Open PHACTS community workshop</u> held at the Royal Society of Chemistry. Great turnout!

#### Powered By:
















© 2013

Powered by 3scale
















Explorer2



ChemBioNavigator Target Dossier





**Pharmatrek** 



Helium



MOE



Collector



Cytophacts



Utopia





Garfield



**KNIME** 



Mol. Data Sheets **PipelinePilot** 





scinav.it





Taverna
















## Sustaining Impact

\* "Software is free like puppies are free they both need money for maintenance"



...and more resource for future development







# Open PHACTS Mission: Integrate Multiple Research Biomedical Data Resources Into A Single Open & Free Access Point






### Kick-Starting Sustainability

**Open PHACTS** 

**Industry Grants** 

Collaboration

**API Users** 
























































SEQUENOMICS

syngenta

AstraZeneca Partner Community











orphanet













ontoforce







Advancing the Chemical Sciences

**Maastricht University** 





code<sup>N</sup>



















inte:ligand





OPF is a not-for-profit membership organisation, supporting the Open PHACTS Discovery Platform:

A sustainable, open, vibrant and interoperable information infrastructure for applied life science research and development.

To reduce the barriers to drug discovery in industry, academia and for small businesses, the Open PHACTS Discovery Platform provides tools and services to interact with multiple integrated and publicly available data sources. To integrate this data, extensive cross-referencing of scientific concepts is needed across all databases.

The Open PHACTS Foundation ensures the sustainability of the Open PHACTS Discovery Platform infrastructure and acts as a hub for relevant scientific research and development.


















**Key Resources** 

▲ Open PHACTS API

**5** Open PHACTS Repository

Subscribe to the Foundation Newsletter

email address

Subscribe

Contact us

info@openphactsfoundation.org

➤ Twitter: @Open PHACTS

#### Membership Benefits



The not-for-profit Foundation maintains the Open PHACTS Discovery Platform, a versatile infrastructure of integrated biomedical data, and actively engages an ecosystem of industry and academic semantic web experts.

Integrated data:
Pharmacological
Physicochemical
Disease Gene
Pathways

#### Steer the direction

- Prioritise new projects
- Get involved with Foundation governance
- Identify development opportunities
- Propose new data sources to include
- Develop new use-cases and workflows

#### **Training opportunities**

Enjoy training opportunities by experts.

#### Early access to releases

Members have early access to infrastructure and platform updates and new releases, including a locally installable system

### Engage a community of experts and peers

The Foundation serves a unique and vibrant scientific community, facilitating collaboration between the pharma industry, academia & SMEs.

Influence the security policy

## Membership Levels Tull Nominate and vote for the Board of Trustees Note for the Board of Trustees Non-voting Get involved in projects and collaborate

www.openphactsfoundation.org

info@openphactsfoundation.org

Open PHACTS Foundation
c/o Royal Society of Chemistry,
Thomas Graham House,
Science Park, Cambridge, CB4 0WF

#### bryn@openphactsfoundation.org

### Acknowledgements









































































Technical University of Denmark
University of Hamburg, Center for
Bioinformatics

BioSolveIT GmBH

Consorci Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

**Novartis** 

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre Swiss Institute of Bioinformatics

ConnectedDiscovery

EMBL-European Bioinformatics Institute

Janssen Esteve Almirall

OpenLink Scibite

The Open PHACTS Foundation

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Aqnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

AstraZeneca

Pfizer